FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068375079> ?p ?o ?g. }

• W2068375079 endingPage "1159" @default.
• W2068375079 startingPage "1153" @default.
• W2068375079 abstract "Background Animal models suggest that immunomodulatory properties of macrolide antibiotics have therapeutic value for patients with acute lung injury (ALI). We investigated the association between receipt of macrolide antibiotics and clinical outcomes in patients with ALI. Methods Secondary analysis of multicenter, randomized controlled trial data from the Acute Respiratory Distress Syndrome Network Lisofylline and Respiratory Management of Acute Lung Injury Trial, which collected detailed data regarding antibiotic use among participants with ALI. Results Forty-seven of 235 participants (20%) received a macrolide antibiotic within 24 h of trial enrollment. Among patients who received a macrolide, erythromycin was the most common (57%), followed by azithromycin (40%). The median duration of macrolide use after study enrollment was 4 days (interquartile range, 2-8 days). Eleven of the 47 (23%) patients who received macrolides died, compared with 67 of the 188 (36%) who did not receive a macrolide (P = .11). Participants administered macrolides were more likely to have pneumonia as an ALI risk factor, were less likely to have nonpulmonary sepsis or to be randomized to low tidal volume ventilation, and had a shorter length of stay prior to trial enrollment. After adjusting for potentially confounding covariates, use of macrolide was associated with lower 180-day mortality (hazard ratio [HR], 0.46; 95% CI, 0.23-0.92; P = .028) and shorter time to successful discontinuation of mechanical ventilation (HR, 1.93; 95% CI, 1.18-3.17; P = .009). In contrast, fluoroquinolone (n = 90) and cephalosporin antibiotics (n = 93) were not associated with improved outcomes. Conclusions Receipt of macrolide antibiotics was associated with improved outcomes in patients with ALI. Animal models suggest that immunomodulatory properties of macrolide antibiotics have therapeutic value for patients with acute lung injury (ALI). We investigated the association between receipt of macrolide antibiotics and clinical outcomes in patients with ALI. Secondary analysis of multicenter, randomized controlled trial data from the Acute Respiratory Distress Syndrome Network Lisofylline and Respiratory Management of Acute Lung Injury Trial, which collected detailed data regarding antibiotic use among participants with ALI. Forty-seven of 235 participants (20%) received a macrolide antibiotic within 24 h of trial enrollment. Among patients who received a macrolide, erythromycin was the most common (57%), followed by azithromycin (40%). The median duration of macrolide use after study enrollment was 4 days (interquartile range, 2-8 days). Eleven of the 47 (23%) patients who received macrolides died, compared with 67 of the 188 (36%) who did not receive a macrolide (P = .11). Participants administered macrolides were more likely to have pneumonia as an ALI risk factor, were less likely to have nonpulmonary sepsis or to be randomized to low tidal volume ventilation, and had a shorter length of stay prior to trial enrollment. After adjusting for potentially confounding covariates, use of macrolide was associated with lower 180-day mortality (hazard ratio [HR], 0.46; 95% CI, 0.23-0.92; P = .028) and shorter time to successful discontinuation of mechanical ventilation (HR, 1.93; 95% CI, 1.18-3.17; P = .009). In contrast, fluoroquinolone (n = 90) and cephalosporin antibiotics (n = 93) were not associated with improved outcomes. Receipt of macrolide antibiotics was associated with improved outcomes in patients with ALI." @default.
• W2068375079 created "2016-06-24" @default.
• W2068375079 creator A5015841346 @default.
• W2068375079 creator A5091604315 @default.
• W2068375079 date "2012-05-01" @default.
• W2068375079 modified "2023-09-26" @default.
• W2068375079 title "Macrolide Antibiotics and Survival in Patients With Acute Lung Injury" @default.
• W2068375079 cites W105869727 @default.
• W2068375079 cites W1692839365 @default.
• W2068375079 cites W1903803846 @default.
• W2068375079 cites W1974498819 @default.
• W2068375079 cites W1978960863 @default.
• W2068375079 cites W1995976051 @default.
• W2068375079 cites W2012846629 @default.
• W2068375079 cites W2018771784 @default.
• W2068375079 cites W2026573053 @default.
• W2068375079 cites W2031604627 @default.
• W2068375079 cites W2032644680 @default.
• W2068375079 cites W2068854215 @default.
• W2068375079 cites W2074488392 @default.
• W2068375079 cites W2075455971 @default.
• W2068375079 cites W2088017501 @default.
• W2068375079 cites W2089925043 @default.
• W2068375079 cites W2100536943 @default.
• W2068375079 cites W2118589594 @default.
• W2068375079 cites W2123178771 @default.
• W2068375079 cites W2132222325 @default.
• W2068375079 cites W2134090167 @default.
• W2068375079 cites W2150291618 @default.
• W2068375079 cites W2154224759 @default.
• W2068375079 cites W2163139616 @default.
• W2068375079 cites W2163987761 @default.
• W2068375079 cites W2168828417 @default.
• W2068375079 cites W2320873518 @default.
• W2068375079 cites W2597070792 @default.
• W2068375079 cites W2598361884 @default.
• W2068375079 cites W31089 @default.
• W2068375079 cites W3132523877 @default.
• W2068375079 cites W4247943214 @default.
• W2068375079 cites W4248053214 @default.
• W2068375079 doi "https://doi.org/10.1378/chest.11-1908" @default.
• W2068375079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3342785" @default.
• W2068375079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22116799" @default.
• W2068375079 hasPublicationYear "2012" @default.
• W2068375079 type Work @default.
• W2068375079 sameAs 2068375079 @default.
• W2068375079 citedByCount "90" @default.
• W2068375079 countsByYear W20683750792012 @default.
• W2068375079 countsByYear W20683750792013 @default.
• W2068375079 countsByYear W20683750792014 @default.
• W2068375079 countsByYear W20683750792015 @default.
• W2068375079 countsByYear W20683750792016 @default.
• W2068375079 countsByYear W20683750792017 @default.
• W2068375079 countsByYear W20683750792018 @default.
• W2068375079 countsByYear W20683750792019 @default.
• W2068375079 countsByYear W20683750792020 @default.
• W2068375079 countsByYear W20683750792021 @default.
• W2068375079 countsByYear W20683750792022 @default.
• W2068375079 countsByYear W20683750792023 @default.
• W2068375079 crossrefType "journal-article" @default.
• W2068375079 hasAuthorship W2068375079A5015841346 @default.
• W2068375079 hasAuthorship W2068375079A5091604315 @default.
• W2068375079 hasBestOaLocation W20683750792 @default.
• W2068375079 hasConcept C119060515 @default.
• W2068375079 hasConcept C126322002 @default.
• W2068375079 hasConcept C168563851 @default.
• W2068375079 hasConcept C207103383 @default.
• W2068375079 hasConcept C2777914695 @default.
• W2068375079 hasConcept C2778155338 @default.
• W2068375079 hasConcept C2778907293 @default.
• W2068375079 hasConcept C2780206985 @default.
• W2068375079 hasConcept C44249647 @default.
• W2068375079 hasConcept C501593827 @default.
• W2068375079 hasConcept C71924100 @default.
• W2068375079 hasConcept C86803240 @default.
• W2068375079 hasConcept C89423630 @default.
• W2068375079 hasConceptScore W2068375079C119060515 @default.
• W2068375079 hasConceptScore W2068375079C126322002 @default.
• W2068375079 hasConceptScore W2068375079C168563851 @default.
• W2068375079 hasConceptScore W2068375079C207103383 @default.
• W2068375079 hasConceptScore W2068375079C2777914695 @default.
• W2068375079 hasConceptScore W2068375079C2778155338 @default.
• W2068375079 hasConceptScore W2068375079C2778907293 @default.
• W2068375079 hasConceptScore W2068375079C2780206985 @default.
• W2068375079 hasConceptScore W2068375079C44249647 @default.
• W2068375079 hasConceptScore W2068375079C501593827 @default.
• W2068375079 hasConceptScore W2068375079C71924100 @default.
• W2068375079 hasConceptScore W2068375079C86803240 @default.
• W2068375079 hasConceptScore W2068375079C89423630 @default.
• W2068375079 hasFunder F4320306127 @default.
• W2068375079 hasFunder F4320337351 @default.
• W2068375079 hasIssue "5" @default.
• W2068375079 hasLocation W20683750791 @default.
• W2068375079 hasLocation W20683750792 @default.
• W2068375079 hasLocation W20683750793 @default.
• W2068375079 hasLocation W20683750794 @default.
• W2068375079 hasOpenAccess W2068375079 @default.
• W2068375079 hasPrimaryLocation W20683750791 @default.

• next